Literature DB >> 35464269

Loco-regional treatments of unresectable hepatocellular carcinoma: safety first.

Jean-Luc Raoul1.   

Abstract

Entities:  

Year:  2022        PMID： 35464269      PMCID： PMC9023825          DOI： 10.21037/hbsn-2021-30

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  10 in total

Review 1.  Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

Authors:  J-L Raoul; B Sangro; A Forner; V Mazzaferro; F Piscaglia; L Bolondi; R Lencioni
Journal:  Cancer Treat Rev       Date:  2010-08-17       Impact factor: 12.111

2.  Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.

Authors:  Jens Ricke; Heinz Josef Klümpen; Holger Amthauer; Irene Bargellini; Peter Bartenstein; Enrico N de Toni; Antonio Gasbarrini; Maciej Pech; Markus Peck-Radosavljevic; Peter Popovič; Olivier Rosmorduc; Eckart Schott; Max Seidensticker; Chris Verslype; Bruno Sangro; Peter Malfertheiner
Journal:  J Hepatol       Date:  2019-08-14       Impact factor: 25.083

Review 3.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2018-04-05       Impact factor: 25.083

4.  SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma.

Authors:  Pierce K H Chow; Mihir Gandhi; Say-Beng Tan; Maung Win Khin; Ariunaa Khasbazar; Janus Ong; Su Pin Choo; Peng Chung Cheow; Chanisa Chotipanich; Kieron Lim; Laurentius A Lesmana; Tjakra W Manuaba; Boon Koon Yoong; Aloysius Raj; Chiong Soon Law; Ian H Y Cua; Rolley R Lobo; Catherine S C Teh; Yun Hwan Kim; Yun Won Jong; Ho-Seong Han; Si-Hyun Bae; Hyun-Ki Yoon; Rheun-Chuan Lee; Chien-Fu Hung; Cheng-Yuan Peng; Po-Chin Liang; Adam Bartlett; Kenneth Y Y Kok; Choon-Hua Thng; Albert Su-Chong Low; Anthony S W Goh; Kiang Hiong Tay; Richard H G Lo; Brian K P Goh; David C E Ng; Ganesh Lekurwale; Wei Ming Liew; Val Gebski; Kenneth S W Mak; Khee Chee Soo
Journal:  J Clin Oncol       Date:  2018-03-02       Impact factor: 44.544

5.  Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma.

Authors:  Jens Ricke; Regina Schinner; Max Seidensticker; Antonio Gasbarrini; Otto M van Delden; Holger Amthauer; Bora Peynircioglu; Irene Bargellini; Roberto Iezzi; Enrico N De Toni; Peter Malfertheiner; Maciej Pech; Bruno Sangro
Journal:  J Hepatol       Date:  2021-08-27       Impact factor: 25.083

6.  A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma.

Authors: 
Journal:  N Engl J Med       Date:  1995-05-11       Impact factor: 91.245

Review 7.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

8.  Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.

Authors:  Valérie Vilgrain; Helena Pereira; Eric Assenat; Boris Guiu; Alina Diana Ilonca; Georges-Philippe Pageaux; Annie Sibert; Mohamed Bouattour; Rachida Lebtahi; Wassim Allaham; Hélène Barraud; Valérie Laurent; Elodie Mathias; Jean-Pierre Bronowicki; Jean-Pierre Tasu; Rémy Perdrisot; Christine Silvain; René Gerolami; Olivier Mundler; Jean-Francois Seitz; Vincent Vidal; Christophe Aubé; Frédéric Oberti; Olivier Couturier; Isabelle Brenot-Rossi; Jean-Luc Raoul; Anthony Sarran; Charlotte Costentin; Emmanuel Itti; Alain Luciani; René Adam; Maïté Lewin; Didier Samuel; Maxime Ronot; Aurelia Dinut; Laurent Castera; Gilles Chatellier
Journal:  Lancet Oncol       Date:  2017-10-26       Impact factor: 41.316

9.  Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study.

Authors:  Masatoshi Kudo; Kazuomi Ueshima; Stephan Chan; Tomohiro Minami; Hirokazu Chishina; Tomoko Aoki; Masahiro Takita; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Mamoru Takenaka; Toshiharu Sakurai; Tomohiro Watanabe; Masahiro Morita; Chikara Ogawa; Yoshiyuki Wada; Masafumi Ikeda; Hiroshi Ishii; Namiki Izumi; Naoshi Nishida
Journal:  Cancers (Basel)       Date:  2019-07-31       Impact factor: 6.639

10.  ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma.

Authors:  Céline Lescure; Florian Estrade; Maud Pedrono; Boris Campillo-Gimenez; Samuel Le Sourd; Marc Pracht; Xavier Palard; Héloïse Bourien; Léa Muzellec; Thomas Uguen; Yan Rolland; Etienne Garin; Julien Edeline
Journal:  Cancers (Basel)       Date:  2021-07-28       Impact factor: 6.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.